Trial Profile
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs ATP 128 (Primary) ; Ezabenlimab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms KISIMA-01
- Sponsors Amal Therapeutics
- 29 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Sep 2023 Results assessing safety, tolerability and immunogenicity of ATP128 alone or in combination with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
- 15 Aug 2022 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.